Bionomics - BNOX STOCK NEWS

Bionomics Limited (ASX: BNO, Nasdaq: BNOX) announced its quarterly cash flow report for the period ending September 30, 2022. The company reported a cash balance of $31.43 million, down from $33.56 million in June. Research and development expenses decreased by 16.28% to $3.50 million. Bionomics is advancing its lead drug candidate, BNC210, through clinical studies for Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD), with topline results for the PREVAIL study expected by the end of 2022. Various activities, including a KOL webinar and participation in conferences, were conducted during the quarter.

Bionomics Limited (Nasdaq: BNOX | ASX: BNO) has announced the receipt of A$4,634,307.30 in a research and development (R&D) tax incentive refund for the financial year ending June 2022. This incentive, provided by the Australian Government, offers a tax offset of up to 43.5% for eligible R&D activities to encourage innovation within Australia. Bionomics is a clinical-stage biopharmaceutical company focused on developing treatments for serious central nervous system disorders, including its lead candidate BNC210 for Social Anxiety Disorder and Post-Traumatic Stress Disorder.

Bionomics Limited (NASDAQ: BNOX, ASX: BNO) is a clinical-stage biopharmaceutical company focused on developing allosteric ion channel modulators for serious CNS disorders. On October 6-7, 2022, the company will participate in the Cantor Neurology & Psychiatry Conference at The Ritz-Carlton in San Francisco. Errol De Souza, Executive Chairman, will join a panel on Emerging Broad Pipeline for Psychiatric Indications on October 7 at 7:50 am PT. An audio webcast will be available on their website.

Bionomics Limited (ASX:BNO, Nasdaq: BNOX) has announced a Key Opinion Leader webinar on BNC210, a novel treatment for Social Anxiety Disorder (SAD), scheduled for October 12, 2022. This first-in-class candidate has received FDA Fast Track Designation for acute SAD treatment. Experts Murray B. Stein, MD, and Charlie Taylor, PhD, will discuss the unmet needs and Bionomics' ongoing clinical studies, including the 150 patient Phase 2 PREVAIL study aiming for topline data by the end of 2022. BNC210 also shows promise for Post-Traumatic Stress Disorder (PTSD).

Bionomics Limited (ASX:BNO, NASDAQ:BNOX), a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences this September. Key events include Citi’s 17th Annual BioPharma Conference in Boston on September 8, H.C. Wainwright 24th Annual Global Investment Conference in New York City on September 12 at 12:30 PM ET, and the Ladenburg Thalmann Healthcare Conference 2022 in New York City on September 29 at 4:00 PM ET. Audio webcasts for select events will be available on their Investors website.

Bionomics Limited (ASX:BNO, Nasdaq:BNOX) reported its financial results for the year ended June 30, 2022. The company focuses on developing BNC210, a treatment for Social Anxiety Disorder and Post-Traumatic Stress Disorder. It has received FDA Fast Track designation and initiated the Phase 2 PREVAIL study for acute SAD treatment, with topline data expected by the end of 2022. Additionally, the ATTUNE study for chronic PTSD treatment is underway. Bionomics completed a US IPO, raising $26.67 million, and has partnered with Merck to advance its Positive Allosteric Modulator program.

Bionomics Limited (BNOX) released its Quarterly Activities and ASX Appendix 4C Cashflow Reports for the quarter ending June 30, 2022. Cash balance was $33.56 million, down from $39.58 million in the previous quarter. R&D expenditure rose by 84.14% to $4.18 million, driven by ongoing Phase 2 trials for BNC210 in treating Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD). Upcoming milestones include topline data for both studies expected by the end of 2022 and the first half of 2023, respectively.

Bionomics Limited (Nasdaq: BNOX | ASX: BNO) announced that Dr. Errol De Souza, Executive Chairman, will participate in a panel on "Unmet Needs and Novel Therapies in Neuropsychiatry" at the William Blair Biotech Focus Conference on July 13, 2022, at 9:00 am ET. He will also conduct one-on-one meetings with investors. Bionomics is focused on developing allosteric ion channel modulators to address serious CNS disorders. Their lead drug, BNC210, targets Social Anxiety Disorder and PTSD. For more information, visit Bionomics' website.

Bionomics Limited (NASDAQ: BNOX) invites shareholders to an investor webinar on June 15, 2022, at 10:30 AM AEST. The Executive Chairman and Vice President will discuss the ongoing Phase 2 trials for Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD), emphasizing the high unmet medical need for new treatments. The presentation will also outline the company's near-term milestones and goals for 2022 and beyond. Interested participants can register via the link provided in the announcement.